Fraxetin (Synonyms: 7,8-Dihydroxy-6-Methoxycoumarin) |
Catalog No.GN10556
One-Click Copy Product Info
|
Fraxetin is a plant-derived O-methylcoumarin.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 574-84-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Fraxetin is a plant-derived O-methylcoumarin [1]. Fraxetin exerts anti-inflammatory effects by directly scavenging reactive oxygen free radicals and activating antioxidant defenses, and intervening in inflammatory signals [2]. Fraxetin has anti-tumor, anti-inflammatory, and neuroprotective effects [3-4].
In MCF-7 cells, Fraxetin (10-60µM; 24h, 48h) significantly inhibited cell proliferation in a concentration and time-dependent manner [5]. In SKOV3 and SW626 cells, Fraxetin (80µM; 12h) suppresses the proliferation, migration, and invasion of ovarian cancer cells by inhibiting the TLR4/STAT3 signaling pathway [6]. In T98G and LN-229 cells, Fraxetin (5-50µM; 48h) inhibited cell viability in a concentration-dependent manner [7].
In C57BL/6J mice, Selenium-dependent glutathione reductase activity is significantly increased in the liver of Fraxetin (25mg/kg; po; 30d) treated mice [8]. In Dextran sulphate sodium (DSS)-induce a mouse model of colitis, Fraxetin (10mg/kg, 30mg/kg, 60mg/kg; po; 8d) alleviates DSS-induced colitis by modulating the inflammatory response, enhancing epithelial barrier integrity and regulating the gut microbiota [9].
References:
[1]. Wang H, Zou DA, Xie K, et al. Antibacterial mechanism of fraxetin against Staphylococcus aureus. Molecular Medicine Reports. 2014 Nov 1; 10(5): 2341-2345.
[2]. Balaha M, Ahmed N, Geddawy A, et al. Fraxetin prevented sodium fluoride-induced chronic pancreatitis in rats: Role of anti-inflammatory, antioxidant, antifibrotic and anti-apoptotic activities. International immunopharmacology. 2021 Apr 1; 93: 107372.
[3]. Ha NM, Son NT. Health benefits of fraxetin: from chemistry to medicine. Archiv der Pharmazie. 2024 Jul; 357(7): 2400092.
[4]. Fang T, Liu L, Liu W. Exploring the mechanism of fraxetin against acute myeloid leukemia through cell experiments and network pharmacology. BMC Complementary Medicine and Therapies. 2024 Jun 10; 24(1): 226.
[5]. Liu G, Liu Z, Yan Y, et al. Effect of fraxetin on proliferation and apoptosis in breast cancer cells. Oncology Letters. 2017 Dec 1; 14(6): 7374-7378.
[6]. Xu R, Ruan Y, Zhang L, et al. Fraxetin suppresses the proliferation, migration, and invasion of ovarian cancer cells by inhibiting the TLR4/STAT3 signaling pathway. Immunopharmacology and Immunotoxicology. 2023 May 4; 45(3): 287-294.
[7]. Yao H, Li X, Pan X, et al. Fraxetin exerts anticancer effect in glioma by suppressing MiR‐21‐3p. Drug Development Research. 2022 Apr; 83(2): 501-511.
[8]. MARTÍN‐ARAGÓN SA, Benedí JM, Villar AM. Modifications on antioxidant capacity and lipid peroxidation in mice under fraxetin treatment. Journal of pharmacy and pharmacology. 1997 Jan; 49(1): 49-52.
[9]. Sun X, Jin X, Wang L, et al. Fraxetin ameliorates symptoms of dextran sulphate sodium-induced colitis in mice. Heliyon. 2024 Jan 15; 10(1).
| Cell experiment [1]: | |
Cell lines | MCF-7 cells |
Preparation Method | MCF-7 cells were seeded in 96-well plates at a concentration of 1×105/mL and each well contained 100µL. After 24h, Fraxetin was added to 10, 20, 40 and 60µM final concentrations. The control group was treated without Fraxetin. The cells were incubated for 24 and 48h at 37℃ in 5% CO2 and then culture medium was changed. |
Reaction Conditions | 10-60μM; 24h, 48h |
Applications | In MCF-7 cells, Fraxetin significantly inhibited cell proliferation in a concentration and time-dependent manner. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | C57BL/6J male 12-month-old mice maintained under natural lighting conditions in a temperature controlled (22 ± 3℃) room and acclimatized to laboratory environment for a minimum of 15 days before experimentation. Animals were segregated into two groups of 12 each: group a, control; and group b, experimental. All mice received a standard pelleted diet and had free access to food and water. The experimental group wastreated orally for 30 days with Fraxetin (25mg/kg) suspended in 10% (v/v) Tween-20 aqueous solution. |
Dosage form | 25mg/kg; po; 30d |
Applications | Selenium-dependent glutathione reductase activity is significantly increased in the liver of Fraxetin treated mice. |
References: | |
| Cas No. | 574-84-5 | SDF | |
| Synonyms | 7,8-Dihydroxy-6-Methoxycoumarin | ||
| Chemical Name | 7,8-dihydroxy-6-methoxychromen-2-one | ||
| Canonical SMILES | COC1=C(C(=C2C(=C1)C=CC(=O)O2)O)O | ||
| Formula | C10H8O5 | M.Wt | 208.17 |
| Solubility | ≥ 20.8mg/mL in DMSO | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8038 mL | 24.0188 mL | 48.0377 mL |
| 5 mM | 960.8 μL | 4.8038 mL | 9.6075 mL |
| 10 mM | 480.4 μL | 2.4019 mL | 4.8038 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)